Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned
Other Lilly and NIH Studies Continue
Executive Summary
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
You may also be interested in...
Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
Executives On The Move: Celectis, AbbVie and More
Recent executive changes in the industry include C-suite changes at Abbvie and Ceylad Oncology. Meanwhile, new directors were appointed at Celectis and Eyepoint Pharmaceuticals, among others.
Citeline And Norstella Merge To Provide End-To-End Solutions For Pharma
Publisher’s Spotlight: Citeline, publisher of HBW Insight, is to merge with fellow pharmaceutical solutions provider Norstella.